Oncology

Bundled payment models offer employers and community oncology practices greater cost predictability while improving patient access, Baird said.

AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.

Rosa Novo discusses tailoring cancer benefits to workforce needs, improving access and prevention, and return-to-work support.

Employers can advance patient-centered oncology care through proactive benefits, quality data, navigation, and tailored support, Amanda Green, MPH, said.

Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.

ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.

AACR urges Congress to protect NIH/NCI funding amid a fight over a contested OMB grantmaking rule.

Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.

Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on the Cover of the October issue of Evidence-Based Oncology.

PBM practices and split benefit coverage for oral vs IV chemotherapy drive high costs; a bill would close the gap for self-funded plans.

Christos Vaklavas, MD, discussed barriers limiting rural oncology access and challenges to adopting resource-intensive therapies.

AI tools can ease administrative burden in community oncology, but practices face adoption, security, compliance, bias, and error concerns.

FDA cut required monitoring for tarlatamab’s first 2 doses from 22-24 hours to 6-8 hours, easing a barrier to community cancer care.

Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including for patients with non–small cell lung cancer.

Five August FDA approvals introduced novel therapies across vaccines, neurology, oncology, myeloma, and dermatomyositis, despite some regulatory pushback.

The final part explores individualized CAR T and bispecific therapy selection in multiple myeloma and the need for stronger academic-community collaboration.

Bioethicists say Kalshi's FDA and clinical trial betting markets risk bias, insider trading, and misleading signals about drug value.

Community oncologists are steadily adopting bispecific antibodies for myeloma, but advance planning and tocilizumab remain key to safe access.

Andrew Kuykendall, MD, lead investigator for the VERIFY trial supporting the approval, said rusfertide is used to treat erythrocytosis in polycythemia vera.

In part 2, Christos Vaklavas, MD, discusses clinical trial complexity and the shift toward more accessible treatment delivery.

Amandeep Godara, MBBS, explained that rural patients with multiple myeloma face various barriers to immunotherapies that may delay treatment.

A cohort study found lower breast cancer screening odds in the most redlined census tracts, independent of present-day social vulnerability.

Christos Vaklavas, MD, discusses geographic and telehealth barriers to cancer care access across Utah and the broader Mountain West.

Shiven B. Patel, MD, MBA, discussed strategies for overcoming tissue limits, delays, and rural access gaps in NSCLC biomarker testing at an IVBM event.

Review finds 91 new lung cancer screening and pulmonary nodule AI tools, but few get external validation or calibration, risking flawed LDCT decisions.